Sector
PharmaceuticalsOpen
₹688Prev. Close
₹681.9Turnover(Lac.)
₹146.09Day's High
₹688Day's Low
₹665.1552 Week's High
₹811.8552 Week's Low
₹534.8Book Value
₹307.8Face Value
₹10Mkt Cap (₹ Cr.)
1,335.38P/E
13.91EPS
48.91Divi. Yield
0.26Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 20.03 | 20.03 | 20.03 | 20.03 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 572.81 | 482.44 | 412.85 | 346.36 |
Net Worth | 592.84 | 502.47 | 432.88 | 366.39 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 376.08 | 324.95 | 304.27 | 310.81 |
yoy growth (%) | 15.73 | 6.79 | -2.1 | 39.21 |
Raw materials | -186.77 | -171.16 | -172.67 | -203.65 |
As % of sales | 49.66 | 52.67 | 56.74 | 65.52 |
Employee costs | -54.89 | -47.5 | -35.05 | -26.73 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 64.04 | 43.09 | 35.74 | 30.05 |
Depreciation | -5.46 | -4.39 | -3.85 | -3.21 |
Tax paid | -14.48 | -10.34 | -8.33 | -8.31 |
Working capital | -8.51 | 25.15 | 13.34 | -4.84 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.73 | 6.79 | -2.1 | 39.21 |
Op profit growth | 29.17 | 8 | 30.85 | 40.73 |
EBIT growth | 39.41 | 15.08 | 15.61 | 39.5 |
Net profit growth | 51.3 | 19.53 | 26.01 | 47.2 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 580.55 | 510.31 | 472.12 | 424.19 | 386.49 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 580.55 | 510.31 | 472.12 | 424.19 | 386.49 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 34.42 | 22.47 | 10 | 5.66 | 11.04 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,809.6 | 155.92 | 4,29,840.86 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,949.85 | 95.23 | 1,58,179.45 | 430 | 0.5 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,592.6 | 30.01 | 1,27,063.03 | 1,178.16 | 0.83 | 3,969.86 | 360.74 |
Mankind Pharma Ltd MANKIND | 2,659.5 | 54.5 | 1,09,233.62 | 634.43 | 0 | 2,529.74 | 269.24 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.65 | 22.33 | 1,07,397.83 | 1,882.1 | 0.62 | 6,678.8 | 322.48 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Kishorbhai M Shah
Managing Director
Mahendra G Patel
Whole-time Director
Hasmukhbhai I Patel
Independent Director
Pirabhai R Suthar
Whole-time Director
Munjal Mahendrabhai Patel
Whole-time Director
Aashish R Patel
Independent Director
Meha Patel
Independent Director
Saurin J Parikh
Director
Rajnikant G Patel
Whole-time Director
Anand Arvindbhai Patel
Company Sec. & Compli. Officer
Trusha Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lincoln Pharmaceuticals Ltd
Summary
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in Jan 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The company was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.96 to part-finance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 2021-22, Lincoln Parenteral Limited (Transferor Company), an er
Read More
The Lincoln Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹666.7 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lincoln Pharmaceuticals Ltd is ₹1335.38 Cr. as of 08 Nov ‘24
The PE and PB ratios of Lincoln Pharmaceuticals Ltd is 13.91 and 2.30 as of 08 Nov ‘24
The 52-week high/low is the highest and lowest price at which a Lincoln Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lincoln Pharmaceuticals Ltd is ₹534.8 and ₹811.85 as of 08 Nov ‘24
Lincoln Pharmaceuticals Ltd's CAGR for 5 Years at 34.22%, 3 Years at 24.61%, 1 Year at 23.29%, 6 Month at 16.42%, 3 Month at 2.74% and 1 Month at 4.71%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice